MYEOV Facilitates the Progression of Bladder Cancer by Upregulating MMP9 Via the TGF‐β‐H3K4me3 Epigenetic Axis
Molecular Carcinogenesis · 2025-10 · 64 (10) · 1708-1723
DOI: 10.1002/mc.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 31.07.2025. Verfasst von Jianang Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Matrix Metalloproteinase 9, Epigenesis, Genetic, Transforming Growth Factor beta. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: This study was supported by Health Commission of Zhejiang Province., Health Commission of Zhejiang Province.
Abstract (Originalsprache)
Bladder cancer (BC) represents the second most prevalent malignant tumor within the urinary system. Its high rates of recurrence and metastasis contribute to an unfavorable prognosis. The myeloma overexpressed gene (MYEOV) has been associated with the progression of various cancers. However, the specific role and underlying mechanisms of MYEOV in BC progression remain to be elucidated. Our research demonstrates that MYEOV is significantly upregulated in BC and correlates with poor clinical outcomes. Reducing or overexpressing MYEOV can inhibit or promote the proliferation and invasive ability of BC. Mechanistically, MYEOV activates the TGF‐β‐H3K4me3 signaling pathway to directly modulate MMP9 promoter activity through epigenetic modifications, thereby enhancing MMP9 expression. Notably, the effects of MYEOV knockdown or overexpression on BC proliferation and invasion can be counteracted by restoring MMP9 expression. Furthermore, NSUN2 modulates the stability of MYEOV mRNA via m5C methylation, leading to its increased expression in BC. Collectively, our findings elucidate the role of MYEOV in facilitating BC progression through the regulation of MMP9 in vitro. In conclusion, our findings identified that MYEOV is a novel target in the development of bladder cancer and offer new insights into potential therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Department of Pathology, Zhuji People's Hospital, Shaoxing, China.
- Zhejiang Provincial People's Hospital, Hangzhou, China.
- School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.
- Department of Pathology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, China.
- Department of Medical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
ORCID-Profile: Jianang Chen
Förderung
- This study was supported by Health Commission of Zhejiang Province.
- Health Commission of Zhejiang Province
Zitieren
APA
Chen, J., Hu, M., Wang, P., Lin, R., Du, S., Chen, X., Li, W., Chen, G., & Chen, H. (2025). MYEOV Facilitates the Progression of Bladder Cancer by Upregulating MMP9 Via the TGF‐β‐H3K4me3 Epigenetic Axis. Molecular Carcinogenesis, 64(10), 1708-1723. https://doi.org/10.1002/mc.70001
Vancouver
Chen J, Hu M, Wang P, Lin R, Du S, Chen X, et al. MYEOV Facilitates the Progression of Bladder Cancer by Upregulating MMP9 Via the TGF‐β‐H3K4me3 Epigenetic Axis. Molecular Carcinogenesis. 2025;64(10):1708-1723. doi:10.1002/mc.70001
BibTeX
@article{Chen2025,
author = {Chen, Jianang and Hu, Menjun and Wang, Peizhen and Lin, Rixu and Du, Shengwei and Chen, Xingan and Li, Wen and Chen, Guorong and Chen, Hanbin},
title = {MYEOV Facilitates the Progression of Bladder Cancer by Upregulating MMP9 Via the TGF‐β‐H3K4me3 Epigenetic Axis},
journal = {Molecular Carcinogenesis},
year = {2025},
volume = {64},
number = {10},
pages = {1708--1723},
doi = {10.1002/mc.70001}
}
EUVIMED